6533b839fe1ef96bd12a6410

RESEARCH PRODUCT

The role of second and third line tyrosine kinase inhibitor monotherapy in EGFR wild-type (and unknown mutational status) advanced non-small-cell lung cancer patients: Findings from a retrospective analysis

R. AlessandroGiovanni SortinoSergio RizzoFrancesco PassigliaL. BlasiTindara FranchinaAntonio PiconeM. AlùL. AgataAlessandro RussoClaudia CelesiaS. GiuseppinaVincenzo AdamoGiuseppe Bronte

subject

Oncologymedicine.medical_specialtybusiness.industrymedicine.drug_classWild typeHematologymedicine.diseaseTyrosine-kinase inhibitorOncologyThird lineInternal medicinemedicineRetrospective analysisMutational statusNon small cellbusinessLung cancerhttps://doi.org/10.1093/annonc/mdv343.47